Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Roxatidine Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roxatidine Acetate SCHEMBL29965995 | 0.96 | HRH2 (1.00) | HRH2HRH3 | |
| SCHEMBL11399763 | 0.96 | HRH2 (1.00) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL1393 | 0.96 | HRH2 (1.00) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL667643 | 0.95 | HRH2 (0.98) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL29389759 | 0.95 | HRH2 (0.98) | HRH2HRH3 | |
| SCHEMBL11182082 | 0.95 | HRH2 (0.98) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL1650455 | 0.94 | HRH2 (0.96) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL9084471 | 0.94 | HRH2 (0.96) | HRH2HRH3 | |
| Roxatidine Acetate SCHEMBL2322201 | 0.91 | HRH2 (0.89) | HRH2HRH3 | |
| SCHEMBL11179081 | 0.87 | HRH2 (0.83) | HRH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-12011432-B2 | Method of modulating ribonucleotide reductase | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| US-20230172911-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| US-20230016609-A1 | MESOPOROUS SILICA NANOPARTICLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-19 | — | — | US | disclosed |
| US-11260127-B2 | Mesoporous silica nanoparticles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210299095-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | CASE WESTERN RESERVE UNIVERSITY | 2021-09-30 | — | — | US | disclosed |
| US-20210220341-A1 | SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2021-07-22 | — | — | US | disclosed |
| US-11065202-B2 | Multi-component nanochains | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210186875-A9 | MULTI-COMPONENT NANOCHAINS | CASE WESTERN RESERVE UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| EP-1140192-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140194-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINED TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140182-A2 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR TOGETHER WITH AN ANTINEOPLASTIC AGENT, OPTIONALLY ALSO TOGETHER WITH RADIATION, IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038719-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038718-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITOR TOGETHER WITH AN ANTINEOPLASTIC AGENTS, OPTIONALLY ALSO TOGETHER WITH RADIATION, IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220341-A1 | SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS | MYADM, MCL1, PRTN3 | HRH2 3238/4885HRH3 3356/4885 |
| US-20210299095-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | RRM2, RRM2B, RRM1 | HRH2 1345/4885HRH3 2545/4885 |
| US-12011432-B2 | Method of modulating ribonucleotide reductase | RRM2, RRM2B, RRM1 | HRH2 1345/4885HRH3 2545/4885 |
| US-20230172911-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | RRM2, RRM2B, RRM1 | HRH2 3087/4885HRH3 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.